Proliferation markers in tumours: Interpretation and clinical value

Journal of Clinical Pathology

Volumn 51, Issue 10, 1998, Pages 716-724

  Van Diest, Paul J ^a   Brugal, Gerard ^b   Baak, Jan P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT ALBERT BONNIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR MARKER;

BONE TUMOR; BRAIN TUMOR; BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; DNA CONTENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MITOSIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOFT TISSUE TUMOR; TUMOR GROWTH; UTERINE CERVIX TUMOR;

EID: 0031784318     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.10.716     Document Type: Review

References (156)

1. Quastler H, Sherman FG. Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 1959;17:420-38.
2. Meyer JS, McDivitt RW. Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest 1986;54:160-4.
3. Baak JPA. Manual of quantitative pathology in cancer diagnosis and prognosis. Berlin: Springer Verlag, 1991.
4. Baak JPA. Mitosis counting in tumors. Hum Pathol 1990;21: 683-5.
5. van Diest PJ, Baak JPA, Matze-Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 1992;23:603-7.
6. Woosley JT. Measuring cell proliferation. Arch Pathol Lab Med 1991;115:555-7.
7. Haapasalo H, Pesonen E, Collan Y. Volume corrected mitotic index (M/V-index). The standard of mitotic activity in neoplasms. Pathol Res Pract 1989; 185:551-4.
8. Going JJ. Efficiently estimated histologic cell counts. Hum Pathol 1994;25:333-6.
9. Simpson JF, Dutt PL, Page DL. Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal. Hum Pathol 1992;23:608-11.
10. Collan YUI, Kuopio T, Baak JPA, et al. Standardized mitotic counts in breast cancer. Evaluation of the method. Pathol Res Pract 1996;192:931-41.
11. Kaman EJ, Smeulders AWM, Verbeek PW, et al. Image processing for mitoses in sections of breast cancer: a feasibility study. Cytometry 1984;5:244-4.
12. Belien JAM, Baak JPA, van Diest PJ, et al. Counting mitoses by image processing in Feulgen stained breast cancer sections: the influence of resolution. Cytometry 1997;28: 135-40.
13. ten Kate TK, Belien JAM, Smeulders AWM, et al. Method for counting mitoses by image processing in Feulgen stained breast cancer sections. Cytometry 1993;14:241-50.
14. Zucker RM, Elstein KH, Easterling RE, et al. Flow cytometric discrimination of mitotic nuclei by right-angle light scatter. Cytometry 1988;9:226-31.
15. di Vinci A, Geido E, Pfeffer U, et al. Quantitative analysis of mitotic and early-G1 cells using monoclonal antibodies against the AF-2 protein. Cytometry 1993;14:421-7.
16. Spina D, Leoncini L, Close P, et al. Growth versus DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. Int J Cancer 1996;66:179-83.
17. Barnard NJ, Hall PA, Lemoine NR, et al. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987;152:287-95.
18. Isola JJ, Helin HJ, Helle MJ, et al. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 1990;65:1180-4.
19. di Stefano D, Mingazzini PL, Scucchi L, et al. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 1991;67:463-71.
20. Weidner N, Moore DH, Ljung BM, et al. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol 1993;17:987-94.
21. Bergers E, Jannink I, van Diest PJ, et al. Influence of fixation delay on mitotic activity and flow cytometric %S-phase. Hum Pathol 1997;28:95-100.
22. Donhuijsen K, Schmidt U, Hirche H, et al. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 1990;21:709-14.
23. Montironi R, Diamanti L, Santinelli A, et al. Computed cell cycle and DNA histogram analysis in image cytometry in breast cancer. J Clin Pathol 1993;46:795-800.
24. Walker RA, Gallacher B. Determination of transforming growth factor betal mRNA expression in breast carcinomas by in situ hybridization. J Pathol 1995;177:123-7.
25. Bosari S, Lee AKC, Tahan SR, et al. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer 1992;70:1943-50.
26. Lee AKC, Wiley B, Dugan JM, et al. Quantitative DNA analysis and proliferation in breast carcinomas. A comparison between image analysis and flow cytometry. Pathol Res Pract 1992;188:428-32.
27. Bergers E, van Diest PJ, Baak JPA. Comparison of 5 cell cycle analysis models applied to 1414 flow cytometric DNA histograms of fresh frozen breast cancer. Clin Commun Cytometry 1997;30:54-60.
28. Bergers E, van Diest PJ, Baak JPA. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: results from the multicenter morphometric mammary carcinoma project. Int J Cancer 1997;74:260-9.
29. Kallioniemi OP, Visakorpi T, Holli K, et al. Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry 1991;12:413-21.
30. Bergers E, Montironi R, van Diest PJ, et al. Inter-laboratory reproducibility of semiautomated cell cycle analysis of flow cytometric DNA-histograms obtained from fresh material of 1295 breast cancer cases. Hum Pathol 1996;27:553-60.
31. Garcia JE, Celis A. Cell-cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision in S-phase. Proc Natl Acad Sci USA 1985;82:3262-6.
32. Siitonen SM, Kallioniemi OP, Isola JJ. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic value in archival paraffin-embedded node- negative breast cancer. Am J Pathol 1993;142:1081-9.
33. Visscher DW, Wykes S, Kubus J, et al. Comparison of PCNA cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer. Breast Cancer Res Treat 1992;22:111-18.
34. van Dierendonck JH, Wijsman JH, Keijzer R, et al. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki67 staining. Am J Pathol 1991;138: 1165-72.
35. Schmitt FC, Pereira EM, Andrade LM, et al. The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor. Pathol Res Pract 1994;190:786-91.
36. Leonardi H, Girlando S, Serio G, et al. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992;45:416-19.
37. Gerdes J, Becker MHG, Key G, et al. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues [letter]. J Pathol 1992;174:1685-7.
38. Guillaud P, de Manoir S, Geigneurin D. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Anal Cell Pathol 1989;1:25-39.
39. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989;59:943-7
40. Marchetti E, Querzoli P, Marzola A, et al. Assessment of proliferative rate of breast cancer by Ki67 monoclonal antibody. Mol Pathol 1990;3:31-5.
41. Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage III breast carcinoma. Significant correlation with prognosis. Cancer 1991;68:549-57.
42. Weidner N, Moore DH, Vartanian R. Correlation of Ki67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol; 1994;25:337-42.
43. Barbareschi M, Girlando S, Mauri FM, et al. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994;102:171-5.
44. Polkowski W, Meijer GA, Baak JP, et al. Reproducibility of p53 and Ki67 immunoquantitation in Barret's esophagus. Anal Qaunt Cytol Histol 1997;19:246-54.
45. van Diest PJ, van Dam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. J Clin Pathol 1997;50:801-4.
46. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T-cells as prognostic marker in Hodgkin's disease. Blood 1997;89:1376-82.
47. Dervan PA, Gilmartin LG, Loftus BM, et al. Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol 1989;92:401-7.
48. Aaltoma S, Lipponen P, Syrjanen K. Nucleolar organizer regions related to morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis in female breast cancer. Pathol Res Pract 1993;189:416-21.
49. Eskelinen M, Lipponen P, Papinaho S, et al. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 1992;51:555-61.
50. Mourad WA, Erkman-Balis B, Livingston S, et al. Argyrophilic nucleolar organizer regions in breast carcinoma. Correlation with DNA flow cytometry, histopathology, and lymph node status. Cancer 1992;69:1739-44.
51. Öfner D, Hittmair A, Marth C, et al. Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORs) and population doubling time in ten breast cancer cell lines. Pathol Res Pract 1992;188:742-6.
52. Bigras G, Marcelpoil R, Brambilla E, et al. Interest of targeting AgNORs measurement in cycling cells: in vivo cell kinetic evaluation of non-small cell lung cancer. Anal Cell Pathol 1996;11:183-98.
53. Jannink I, Risberg B, van Diest PJ, et al. Heterogeneity of mitoses counting in breast cancer. Histopathology 1996;29: 421-8.
54. Bergers E, van Diest PJ, Baak JPA. Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 1996;49:931-7.
55. Verhoeven D, Bourgeois N, Derde MP, et al. Comparison of cell growth in different parts of breast cancers. Histopathology 1990;17:505-9.
56. Coons SW, Johnson PC. Regional heterogeneity in the DNA content of human gliomas. Cancer 1993;72:3052-60.
57. Roessler K, Nasel C, Czech T, et al. Histological heterogeneity of neuroradiologically suspected low grade gliomas detected by xenon enhanced computerized tomography (CT). Acta Neurochir 1996;138:1341-7.
58. Jacob R, Welkoborsky HJ, Mann WJ, et al. Heterogeneity of squamous cell carcinomas of the head and neck analysis of tumor biologic factors and proliferation rates. Laryngoscope 1996;106:1170-5.
59. Kressner U, Lindmark G, Gerdin B, et al. Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res 1995;15:2755-61.
60. Muller W, Schneiders A, Meijer S, et al. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759-65.
61. Barrans S, Randerson J, Evans P, et al. Heterogeneity in cell proliferation and expression of p53 and bcl-2 during indolent phase of germinal centre cell lymphoma: an explanation for clinical variability. Br J Haematol 1995;90:830-6.
62. Tubiana M, Pejovic MH, Koscielny S, et al. Growth rate, kinetics of tumor cell proliferation, and long-term outcome in human breast cancer. Int J Cancer 1989;44:17-22.
63. Silvestrini R, Daidone MG, Luisi A, et al. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological information provided by 3H-thymidine labelling index. Int J Cancer 1997;74:122-7.
64. Mouriquand J, Gozlan-Fior M, Villemain D, et al. Value of cytoprognostic classification in breast carcinomas. J Clin Pathol 1986;39:489-96.
65. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
66. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991;19:403-10.
67. le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
68. Joensuu H, Toikkanen S, Klemi PJ. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990;66:331-40.
69. Elston CW, Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987.
70. Baak JPA, Kurver PHJ, Snoo-Nieuwlaat AJE, et al. Prognostic indicators in breast cancer morphometric methods. Histopathology 1982;6:327-39.
71. Baak JPA, van Dop H, Kurver PHJ, et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985;56:374-82.
72. Baak JPA, Chin D, van Diest PJ, et al. Comparative long term prognostic value of quantitative Her2/Neu protein expression, DNA ploidy, morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 1991;64:215-22.
73. van Diest PJ, Baak JPA. The morphometric multivariate prognostic index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum Pathol 1991;22:326-30.
74. van Diest PJ, Baak JPA, Matze-Cok P, et al. Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression: preliminary results. Pathol Res Pract 1992;188: 344-9.
75. van Diest PJ, Jannink I, Matze-Cok E, et al. Comparative prognostic value of lymph node metastases and primary tumor quantitative variables in breast cancer. Electromic Journal of Pathology and Histology 1995;1:952-02.
76. van der Linden JC, Baak JPA, Lindeman J. et al. Prospective evaluation of the prognostic value of morphometry in primary breast cancer patients. J Clin Pathol 1987;40:302-6.
77. van der Linden JC, Lindeman J, Baak JPA, et al. The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 1989;10:56-61.
78. Tosi P, Luzi P, Sforza V, et al. Correlation between morphometrical parameters and disease free-survival in ductal breast cancer treated only by surgery. Appl Pathol 1986;4:33-42.
79. Uyterlinde AM, Schipper NW, Baak JPA, et al. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol 1988;89:301-7.
80. Uyterlinde AM, Baak JPA, Schipper NW, et al. Further evaluation of morphometric and flow cytometric features in breast cancer patients with long term follow up. Int J Cancer 1990;45:1-7.
81. Uyterlinde AM, Baak JPA, Schipper NW, et al. Prognostic value of morphometry and DNA flow cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer 1991;48:173-81.
82. Biesterfeld S, Noll I, Noll E, et al. Mitotic frequency as a prognostic factor in breast cancer. Hum Pathol 1995;26:47-52.
83. Baak JPA, van Diest PJ. The multicenter morphometric mammary carcinoma project. A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in the Netherlands. Pathol Res Pract 1989;185:664-70.
84. Aaltomaa S, Lipponen P, Eskelinen M, et al. Prognostic factors in axillary lymph node-negative (pN ) breast carcinomas. Eur J Cancer 1991;27:1555-9.
85. Aaltomaa S, Lipponen P, Eskelinen M, et al. Prognostic factors after 5 years follow-up in female breast cancer. Oncology 1992;49:93-8.
86. Aaltoma S, Lipponen P, Papinaho S, et al. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Res Clin Oncol 1993;119:288-94.
87. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991;68:1309-17.
88. Lipponen PK, Collan Y, Eskelmen MJ. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int J Surg 1991;76:245-9.
89. Lipponen P, Eskelinen M, Papinaho S, et al. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Anticancer Res 1992;12:667-82.
90. Bonsing BA, Beerman H, Kuipers-Dijkshoorn N, et al. High levels of DNA index heterogeneity in advanced breast cancer. Cancer 1993;71:382-91.
91. Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer 1993;71:3926-31.
92. Wintzer HO, Zipfel I, Schulte-Moenting J, et al. Ki67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
93. Beck T, Weller EE, Weikel W, et al. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 1995;57:96-104.
94. Dettmar P, Harbeck N, Thomssen C, et al. Prognostic impact of proliferation-associated factors MIB1 and S-phase in node-negative breast cancer. Br J Cancer 1997; 75:1525-33.
95. Jensen V, Ladekarl M, Holm-Nielsen P, et al. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node negative breast cancer. J Pathol 1995;176:343-52.
96. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, Mib 1,pS2 and GST pi. Br J Cancer 1996;74:1458-65.
97. Pietilainen T, Lipponen P, Aaltomaa S, et al. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 1996;122:687-92.
98. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:1546-9.
99. Veronse SM, Maisano C, Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation markers in breast cancer. Anticancer Res 1995;15:2717-22.
100. Schoenborn I, Minguillon C, Moehner M, et al. PCNA as a potential prognostic marker in breast cancer. Breast 1994; 3:97-102.
101. Tahan SR, Neuberg DS, Dieffenbach A, et al. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993;71:3552-9.
102. Thomas M, Noguchi M, Kitagawa H, et al. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol 1993;46:525-8.
103. Sumithran E, Susil BJ, Lai-Leng-Looi. The prognostic significance of grading in borderline mucinous tumours of the ovary. Hum Pathol 1988;19:15-18.
104. Baak JPA, Fox H, Langley FA, et al. The prognostic value of morphometry in ovarian epithelial tumors of borderline malignancy. Int J Gynecol Pathol 1985;4:186-91.
105. Baak JPA, Abeler V, Broeckaert MAM, et al. Morphometry and DNA cytometry have strong and additional prognostic value in borderline ovarian tumours with long term follow up [abstr]. J Pathol 1995;176:49A.
106. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988;62:2212-22.
107. Baak JPA, Wisse-Brekelmans ECM, Langley FA, et al. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 1986;39:1340-6.
108. Baak JPA. Prognostic value of histopathological morphometry in endocrine-related cancer. Rev Endocr Rel Cancer 1987;27:21-4.
109. Haapasalo H, Collan Y, Atkin NB, et al. Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology 1989;15:167-78.
110. Haapasalo H, Collan Y, Seppa A, et al. Prognostic value of ovarian carcinoma grading methods a method comparison study. Histopathology 1990;16:1-7.
111. Baak JPA, Schipper NW, Wisse-Brekelmans ECM, et al. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer 1988;57:503-8.
112. Rodenburg CJ, Cornelisse CJ, Hermans J, et al. DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: a step forward in predicting the clinical outcome. Gynecol Oncol 1988;29:176-87.
113. Kuhn W, Kaufmann M, Feichter GE, et al. Psammoma body content and DNA flow cytometric results as prognostic factors in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1988;9:234-41.
114. van der Heul R. Het periostale ossificerende fibrosarcoom en de gradering van osteosarcomen. Leiden: University of Leiden, 1962 [thesis].
115. Price CHG. Osteogenic sarcoma. An analysis of survival and its relationship to histologic grading and structure. J Bone Joint Surg [Br] 1961;43:300-13.
116. Cuvelier CA, Roels HJ. Cytophotometric studies of the nuclear DNA content in cartilaginous tumours. Cancer 1979;44:1363-74.
117. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-31.
118. van der Werff-Messing B, van Unnik JAM. Fibrosarcoma of the soft tissues. Cancer 1965;18:1113-23.
119. Ruiter DJ, van Rijssel TG, van der Velde EA. Aneurysmal bone cysts. A clinicopathological study of 105 cases. Cancer 1977;39:2231-9.
120. Ruiter DJ, Cornelisse CJ, van Rijssel TG, et al. Aneurysmal bone cyst and teleangiectatic osteosarcoma. Virchows Arch [A] 1977;373:311-25.
121. Enzinger FM, Weiss SW. Benign tumors of smooth muscle. In: Enzinger FM, Weiss SW, eds. Soft tissue tumours. St Louis: CV Mosby, 1988:385.
122. Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. New York: Springer, 1987:385.
123. Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992;97:14-20.
124. Rosai J. Female reproductive system uterus-corpus. In: Rosai J, ed. Ackerman's surgical pathology. St Louis: CV Mosby, 1989:1088.
125. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. Am J Surg Pathol 1994; 18:535-58.
126. Jeffers MD, Oakes SJ, Richmond JA, et al. Proliferation, ploidy and prognosis in uterine smooth muscle tumours. Histopathology 1996;29:217-23.
127. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma vs bizarre and cellular leiomyomas of the uterus: a comparative study based on the Ki67 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry and muscle specific antigens. Int J Gynecol Pathol 1995;14:134-42.
128. Larson B, Silfersward C, Nilsson B, et al. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936 1981. Acta Oncol 1990;29:185-91.
129. Tavassoli FA, Norris HJ. Mesenchymal tumors of the uterus. VII. A clinicopathological study of 60 endometrial stromal nodules. Histopathology 1981;5:1-10.
130. Carrillo R, Candia A, Rodriques-Peralto JL, et al. Prognostic significance of DNA ploidy and proliferate index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997;28:160-5.
131. Michie BA, Black C, Reid RP, et al. Image analysis derived ploidy and proliferation indices in soft tissue sarcomas: comparison with clinical outcome. J Clin Paihol 1994;47: 443-7.
132. Myhre Jensen O, Kaae S, Madsen HE, et al. Histopathological grading in soft tissue tumours. Relation to survival in 261 surgically treated patients. Acta Pathol Microbiol Scand [A] 1983;91:145-51.
133. van Unnik JAM, Coindre JM, Contesso G, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. In: Ryan JR, Baker LO, eds. Recent concept in sarcoma treatment. Dordrecht: Kluwer, 1988.
134. van Unnik JAM, Coindre JM, Contesso G, et al. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1993;29A: 2089-93.
135. Coindre JM, Trojani M, Contesso G, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986;58:306-9.
136. Rooser BO, Willen H, Hugoson A, et al. Prognostic factors in synovial sarcoma. Cancer 1989;63:2182-5.
137. Rudolph P, Kellner U, Chassevent A, et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am J Pathol 1997;150:1997-2007.
138. Choong PF, Akerman M, Willen H, et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotypespecific? APMIS 1995;103:797-805.
139. Drobnjak M, Latres E, Pollack D, et al. Prognostic-implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-54.
140. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic factors for adult soft tissue sarcomas. J Clin Oncol 1997;15:3249-57.
141. Collin F, Chassevent A, Bonichon F, et al. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. Cancer 1997;79:2371-9.
142. Schmidt RA, Conrad EU, Collins C, et al. Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 1993;72:2593-601.
143. Daumas-Duport C, Scheithauer B, O'Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
144. de la Monte SM, Flickinger J. Histopathologic features predicting recurrence of meningeomas following subtotal resection. Am J Surg Pathol 1986;10:836-43.
145. Akerman M, Brandt L, Johnson S, et al. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer 1987;55:219-23.
146. Griffin NR, Howard MR, Quirke P, et al. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol 1988;41:866-70.
147. Schrape S, Jones DB, Wright DH. Comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphomas. Br J Cancer 1987;55:283-6.
148. Hall PA, Richard MA, Gregory WM, et al. The prognostic significance of Ki67 immunostainmg in non-Hodgkin's lymphomas. J Pathol 1988;154:223-35.
149. Gerdes J, Stein H, Rivano MT, et al. Prognostic relevance of tumour cell growth fraction in malignant non-Hodgkin's lymphoma. Lancet 1987;ii:448-9.
150. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157-60.
151. Bulten J, van der Laak JAWM, Gemmink JH, et al. MIB1, promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 1996;178:268-73.
152. Dellas A, Schultheiss E, Holzgreve W, et al. Investigation of the Bcl-2 and C-myc expression in relationship to the Ki67 index in cervical intraepithelial neoplasia. Int J Gynecol Pathol 1997;16:212-18.
153. McCluggage WG, Buhidma M, Tang I., et al. Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. Int J Gynecol Pathol 1996;15:131-6.
154. Payne S, Kernohan NM, Walker R. Proliferation in the normal cervix and in preinvasive cervical lesions. J Clin Pathol 1996;49:667-71.
155. Hall PA, Levison DA. Assessment of cell proliferation. J Clin Pathol 1990;43:184-92.
156. van de Schepop HAM, de Jong JS, van Diest PJ, et al. Apoptosis counting in breast cancer: a methodological study. J Clin Pathol Mol Pathol 1996;49:M214-17.